Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Levofloxacin complex preparation and preparation method thereof

A technology of levofloxacin and compound preparation, which is applied in the directions of pharmaceutical formulations, active ingredients of heterocyclic compounds, medical preparations containing active ingredients, etc., can solve the problems of reducing the therapeutic effect, drug resistance of levofloxacin, etc., and achieves the improvement of the therapeutic effect and strong killing. sterilization effect and the effect of reducing drug resistance

Inactive Publication Date: 2013-03-13
DINGZHENG ANIMAL PHARMA TIANJIN
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Levofloxacin is widely used in clinical practice due to its better efficacy, but this leads to the resistance of some bacteria to levofloxacin, thereby reducing its therapeutic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0024] The preparation method of above-mentioned levofloxacin compound preparation, comprises the following steps:

[0025] ⑴Add levofloxacin and auxiliary ingredients into water one by one in order;

[0026] (2) Continue to add co-solvent until levofloxacin and auxiliary components are completely dissolved;

[0027] (3) adding antioxidant in the solution of step (2);

[0028] (4) After the solution of step (3) is made to volume with water, the finished product is obtained.

[0029] Wherein, step (4) is followed by 0.22 μm microporous membrane filtration. The co-solvent is a mixture of sodium hydroxide, tartaric acid and lactic acid or a mixture of polyvinylpyrrolidone and polyethylene glycol 6000 or arginine and polyethylene glycol 6000. Antioxidants are potassium sorbate, sodium benzoate or sodium metabisulfite.

Embodiment 1

[0031] The preparation process of above-mentioned preparation is:

[0032] (1) Add 10 grams of levofloxacin and 8 grams of ampicillin sodium to 50 ml of purified water one by one;

[0033] (2) Continue to add 1 gram of sodium hydroxide, 3 grams of tartaric acid and 5ml of lactic acid until the substances added in step (1) of purified water are completely dissolved;

[0034] (3) Add 0.2 gram of potassium sorbate to the liquid of step (2);

[0035] (4) the product of step (3) is settled to 100 milliliters;

[0036] (5) Then filter with a 0.22μm microporous membrane.

[0037] ⑹The finished product is obtained by subpackaging.

Embodiment 2

[0039] The preparation process of above-mentioned preparation is:

[0040] (1) Add 10 levofloxacin and 5 gentamicin sulfate to 50 ml purified water one by one;

[0041] (2) Continue to add 10g of polyvinylpyrrolidone and 5g of polyethylene glycol 6000 until step (1) the substance added to the purified water is completely dissolved;

[0042] (3) Add 0.2 gram of antioxidant sodium benzoate to the liquid of step (2);

[0043] (4) the product of step (3) is settled to 100 milliliters;

[0044] (5) Then filter with a 0.22μm microporous membrane.

[0045] ⑹The finished product is obtained by subpackaging.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a levofloxacin complex preparation. The levofloxacin complex preparation is characterized by comprising 10-20 parts of levofloxacin and auxiliary ingredients, and the auxiliary ingredients comprise 5-10 parts of ampicillin sodium, 3-5 parts of gentamicin sulphate or 3-5 parts of amoxicillin. According to the levofloxacin complex preparation, the levofloxacin and auxiliary ingredients are organically combined together, all components are coordinated and effected, the drug resistance of bacteria to the levofloxacin can be reduced, the antibacterial spectrum of the levofloxacin can be extended, the treatment effect can be improved, the clinical trials show that the levofloxacin complex preparation has stronger killing action on escherichia coli, salmonella, staphylococcus aureus, streptococcus pneumoniae, penicillin-resistant strain and the like, thereby being a preparation with high-efficiency and broad-spectrum antibacterial functions.

Description

technical field [0001] The invention relates to the technical field of levofloxacin preparations, in particular to a levofloxacin compound preparation and a preparation method thereof. Background technique [0002] Levofloxacin is a new generation of optically active quinolone antibacterial agent. Its main mechanism of action is to hinder the activity of DNA helicase, and its strength is twice that of ofloxacin. Levofloxacin has a broad-spectrum antibacterial effect on Gram-positive bacteria and negative bacteria including anaerobic bacteria. Intestinal bacteria including Escherichia coli, Klebsiella, Serratia, Proteus, glucose non-fermenting Gram-negative flora including Pseudomonas aeruginosa, Haemophilus influenzae , Neisseria gonorrhoeae, etc. have shown strong antibacterial activity. [0003] Because levofloxacin has better drug efficacy, it is widely used in clinical practice, but this leads to the resistance of some bacteria to levofloxacin, thereby reducing its the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/5383A61K31/43A61K31/7036A61P31/04
CPCY02A50/30
Inventor 刘鼎阔王立红赵云英赵晶晶张俊霞
Owner DINGZHENG ANIMAL PHARMA TIANJIN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products